Phase I study of CAR T cell therapy in paediatric leukaemia adult lymphoma patients at Tata Hospital shows positive results

The phase I clinical trial of CAR-T cell therapy in paediatric-acute lymphocytic leukaemia (ALL) and adult B-cell lymphoma patients at Tata Memorial Hospital (TMH) showed positive outcome. About six paediatric patients and 10 adult patients have been treated respectively in the phase I clinical trials. The final product was manufactured in the immuno-engineering lab of BSBE in IIT Bombay. Dr. Gaurav Narula is the principal investigator for paediatric leukaemia (ALL) study and Dr Hasmukh Jain is the principal investigator for adult lymphoma (DLBCL) study. This is India's first indigenously developed technology for cancer treatment developed at IIT Bombay in collaboration with TMH. The trial is sponsored by ImmunoACT, a clinical stage cell and gene therapy company based in Mumbai. Incubated at SINE (Society for Innovation & Entrepreneurship) at IIT Bombay in 2018, the company's vision is to make CAR-T treatment accessible to all and bring new cutting-edge cell and gene therapies to India. IIT Bombay and TMH based in Mumbai started their R&D collaboration in 2015 to develop the novel CAR-T cell therapy platform for cancers and immune-disorders. Dr Rahul Purwar, Associate Professor, IIT Bombay (on-lien) and currently appointed as CEO of ImmunoACT, designed and developed the indigenous CAR-T platform and patented anti-CD19 CAR-T product (HCAR19). To expand the production and take the CAR-T therapy at commercial scale, ImmunoACT has set up an integrated state-of-the-art cGMP facility in MIDC Rabale, Navi Mumbai. The company has tied up with multiple leading hospitals across the country for its phase II/III clinical trials apart from its principal partner TMH. In early 2021, HCAR19 product entered into two phase 1 clinical trials at TMH, Mumbai. The patient-scale HCAR19 were manufactured in a cGMP facility of IIT Bombay.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!